UTILIZATION MANAGEMENT MEDICAL POLICY

Coverage Summary

This policy covers a range of Factor VIII products including extended half‑life recombinant agents (Adynovate, Eloctate, Esperoct, Jivi), standard half‑life recombinant agents (Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha), plasma‑derived Factor VIII without substantial vWF (Hemofil M), and select von Willebrand‑containing concentrates (Alphanate, Humate‑P, Koate, Wilate) for the management of Hemophilia A and von Willebrand disease (VWD). Disease severity classification and clinical roles for these products (prophylaxis, on‑demand treatment, perioperative management, and immune tolerance therapy where applicable) are described. Recommendations align with national guidance (MASAC and ISTH) and note that Prior Authorization is recommended for these agents with approval recommended when prescriber, indication, and dosing criteria are met.

Key thresholds & headline stats

Typical Approval Duration1 year

Authorization RequirementPrior Authorization

Routine prophylaxis dose (EHL products)up to 100 IU/kg no more frequently than twice weekly

On-demand dose (EHL products)up to 65 IU/kg no more frequently than once every 8 hours for up to 10 doses per episode

Routine prophylaxis dose (SHL products)up to 60 IU/kg no more frequently than every other day (three or four times weekly)

On-demand dose (SHL products)up to 50 IU/kg no more frequently than once every 6 hours for up to 10 doses per episode

Immune tolerance therapyup to 200 IU/kg once daily

VWD dosing (VWF:RCo)up to 80 IU VWF:RCo/kg no more frequently than once every 8 hours for up to 10 days

Medical-Necessity Criteria — General

Recommended Authorization Criteria - General

Prior Authorization is recommended for medical benefit coverage. Approval recommended for those who meet the Criteria and Dosing for the listed indications; prescribed by or in consultation with a hemophilia specialist.

ALL of the following

Agent is one of the listed Factor VIII or von Willebrand-containing products (Adynovate, Eloctate, Esperoct, Jivi, Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil M, Alphanate, Humate-P, Koate, Wilate)
Indication is an FDA-approved indication (Hemophilia A or VWD where specified) or other indication listed in recommended criteria
Prescribed by or in consultation with a hemophilia specialist
Approval duration: up to 1 year (or duration noted per agent)

Medical-Necessity Criteria — Dosing (EHL & SHL Recombinant Products)

Specific Dosing Criteria — Extended Half-Life and Standard Half-Life Recombinant Products (Adynovate, Eloctate, Esperoct, Jivi, Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha)

Approve ONE of the following dosing regimens appropriate to agent (A or B) and indication.

ANY of the following

A (for Adynovate, Eloctate, Esperoct, Jivi)
- Routine prophylaxis: approve up to 100 IU per kg intravenously no more frequently than twice weekly
- On-demand treatment and control of bleeding episodes: approve up to 65 IU per kg intravenously no more frequently than once every 8 hours for up to 10 doses per episode
- Perioperative management: approve up to 65 IU per kg intravenously no more frequently than once every 6 hours for up to 10 doses per procedure

Medical-Necessity Criteria — Plasma-derived Hemofil M and Koate

Hemofil M and Koate Dosing Criteria

Approve for Hemophilia A for 1 year if prescribed by or in consultation with a hemophilia specialist.

ALL of the following

Routine prophylaxis: approve up to 50 IU per kg intravenously no more frequently than every other day (three or four times weekly)
Immune tolerance therapy: approve up to 200 IU per kg intravenously no more frequently than once daily
On-demand treatment and perioperative management: approve up to 50 IU per kg intravenously no more frequently than once every 6 hours for up to 10 doses per episode or procedure

Medical-Necessity Criteria — Alphanate, Humate-P, Wilate (Hemophilia A & VWD)

Alphanate, Humate-P, Wilate Dosing Criteria (Hemophilia A and VWD)

Approve for Hemophilia A for 1 year and for von Willebrand disease when prescribed by or in consultation with a hemophilia specialist. Dosing options below (A, B, C).

ANY of the following

Hemophilia A dosing
- Routine prophylaxis: approve up to 50 IU per kg intravenously no more frequently than every other day (three or four times weekly)
- On-demand/perioperative: approve up to 50 IU per kg intravenously no more frequently than once every 6 hours for up to 10 doses per episode or procedure
- Immune tolerance therapy: approve up to 200 IU per kg intravenously no more frequently than once daily
von Willebrand Disease dosing

Not Recommended / Exclusions

Conditions Not Recommended for Approval

Coverage exclusions

ALL of the following

Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria
Criteria will be updated as new published data are available.

Coding

Products listed in policy (drug names)mixed

Adynovate	Antihemophilic Factor PEGylated intravenous infusion (Baxalta/Takeda)
Eloctate	Antihemophilic Factor Fc fusion protein intravenous infusion (Bioverativ/Sanofi)
Esperoct	Antihemophilic factor glycopegylated intravenous infusion (Novo Nordisk)
Jivi	Antihemophilic Factor PEGylated-aucl intravenous infusion (Bayer)
Afstyla	Antihemophilic Factor single chain intravenous infusion (CSL Behring)
Advate	Antihemophilic Factor intravenous infusion (Baxalta/Takeda)
Kogenate FS	Antihemophilic Factor intravenous infusion (Bayer)
Novoeight	Antihemophilic Factor intravenous infusion (Novo Nordisk)
Kovaltry	Antihemophilic Factor intravenous infusion (Bayer)
Nuwiq	Antihemophilic Factor intravenous infusion (Octapharma)

1–10 of 17

1/2

Provider Actions

Prior Authorization

Prior Authorization Required

Prior authorization is recommended for the listed Factor VIII and von Willebrand-containing products; approval is recommended when criteria and dosing are met.

Codes: none

Documentation Required

Specialist Prescription/Consultation Requirement

Agent must be prescribed by or in consultation with a hemophilia specialist due to specialized evaluation, diagnosis, monitoring and dosing.

Background & Definitions

Referenced guidance includes the National Bleeding Disorders Foundation (MASAC) recommendations and the International Society on Thrombosis and Haemostasis (ISTH) clinical practice guidance (2024), which recognize the role of Factor VIII products in hemophilia management and the role of vWF‑containing products in VWD. The policy implements these recommendations into utilization management by listing covered products, specifying specialist prescription/consultation requirements, and providing detailed dosing and duration criteria for authorization.

Term	Definition
Immune tolerance therapy (immune tolerance induction)
Daily high-dose factor replacement therapy intended to eradicate inhibitors.
VWF:RCo
Von Willebrand Factor activity measured with the Ristocetin cofactor assay.

Revision History

03/22/2023annual_revision

Annual Revision: Removed Helixate/Helixate FS and Monoclate P from the policy as both products are obsolete. (History notes removal)

12/13/2023selected_revision

Selected Revision: Added dosing for Humate P, Alphanate, and Wilate for von Willebrand disease routine prophylaxis.

11/13/2024selected_revision

Selected Revision: Added dosing for Adynovate, Eloctate, Esperoct, and Jivi immune tolerance therapy (immune tolerance induction).